Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Integrating the Latest HIV Treatment Safety and Tolerability Data Into Clinical Practice
  • CME
  • CE

Kassem Bourgi, MD
Released: August 11, 2020
Back Next

References

  1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. December 18, 2019. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0. Accessed July 30, 2020.
  2. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320:379-396.
  3. US Food and Drug Administration. FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-two-drug-complete-regimen-hiv-infected-patients-who-have-never-received. Accessed July 30, 2020.
  4. Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2019;[Epub].
  5. Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70:1267.
  6. Bourgi K, Jenkins CA, Rebeiro PF, et al. Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020;23:e25484.
  7. Silverberg M, Leyden W, Alexeeff S, et al. Changes in body mass index over time in persons with and without HIV. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OAB0603.
  8. Thompson-Paul AM, Wei SC, Mattson CL, et al. Obesity among HIV-infected adults receiving medical care in the United States: data from the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination Survey. Medicine (Baltimore). 2015;94:e1081.
  9. Venter F, Moorhouse M, Sokhela S, et al. The ADVANCE trial: phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OAXLB0104.
  10. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381:803-815.
  11. ClinicalTrials.gov. ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (ADVANCE). Available at: https://clinicaltrials.gov/ct2/show/NCT03122262. Accessed July 30, 2020.
  12. Hill A, Venter F, Delaporte E, et al. Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials. Program and abstracts of the 10th IAS Conference on HIV Science; July 21-24, 2019; Mexico City, Mexico. Abstract MOAX0102LB.
  13. Ramsay M, Crowther NJ, Agongo G, et al. Regional and sex-specific variation in BMI distribution in four sub-Saharan African countries: the H3Africa AWI-Gen study. Glob Health Action. 2018;11(suppl 2):1556561.
  14. Griesel R, Maartens G, Sokhela S, et al. CYP2B6 genotype and weight-gain differences between dolutegravir and efavirenz. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020. Abstract 82.
  15. Leonard M, Bourgi K, Koethe JR, et al. Pharmacogenetics of weight gain after switch from efavirenz to integrase inhibitors. Program and abstracts of the 2019 Conference on Retroviruses and Opportunistic Infections; March 4-7, 2019; Seattle, Washington. Abstr 472.
  16. Chow W, Donga P, Côté-Sergent A, et al. Weight/body mass index (BMI) gains following initiation of integrase strand transfer inhibitor (INSTI) versus protease inhibitor (PI) among people living with human immunodeficiency virus (PLWH) in the United States. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract PEB0194.
  17. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide [package insert]. Titusville, NJ: Janssen Products, LP; 2018.
  18. Mallon P, Brunet L, Hsu R, et al. Weight gain before and after switch from TDF to TAF. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OAB0604.
  19. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2015.
  20. van Wyk J, Ait-Khaled M, Santos J, et al. Improved metabolic parameters after switching from TAF-based 3- or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): the TANGO study. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OAB0606.
  21. Huhn GD, Shamblaw DJ, Baril JG, et al. Atherosclerotic cardiovascular disease risk profile of tenofovir alafenamide versus tenofovir disoproxil fumarate. Open Forum Infect Dis. 2020;7:ofz472.
  22. Tsiodras S, Mantozoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050-2056.
  23. Kumar P, Johnson M, Xu ZJ, et al. Weight changes after switch to doravirine/lamivudine/TDF in the DRIVE-SHIFT trial. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OAB0605.
  24. Johnson M, Kumar P, Molina JM, et al. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2019;81:463-472.
  25. Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus–1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2019;68:535-544.
  26. Ake J. Weight gain and hyperglycemia during the dolutegravir transition in Africa. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OAB0602.
  27. Dorward J, Lesssells R, Drain PK, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. 2018;5:e400-e404.
  28. Ramgopol M, Maggiolo F, Ward D, et al. Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged ≥ 65 years demonstrating safety and efficacy: week 48 results. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OAB0403.
  29. Appelman B, Van Den Berk G, De Regt M, et al. Cardiac events in HIV-infected patients who use tenofovir alafenamide (TAF). Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020. Abstract 655.
  30. US Department of Health and Human Services. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. April 14, 2020. Available at: https://aidsinfo.nih.gov/guidelines/html/3/perinatal/224/whats-new-in-the-guidelines. Accessed July 30, 2020.
  31. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018;379:979-981.
  32. Zash R, Holmes L, Diseko M, et al. Neural tube defects by antiretroviral and HIV exposure in the Tsepamo study, Botswana. Program and abstracts of the 10th IAS Conference on HIV Science; July 21-24, 2019; Mexico City, Mexico. Abstract MOAX0105LB.
  33. Zash R. Holmes L, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OAXLB0102.
  34. Asif S, Baxevanidi E, Hill A, et al. The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trial. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OABLB0103.
  35. Asif S, Baxevanidi E, Hill A, et al. Faster virological suppression with dolutegravir versus efavirenz in pregnancy does not lower the risk of HIV mother-to-child-transmission: A meta-analysis of 5 clinical trials in 1074 pregnant women. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OABLB0105.
  36. Matovu FK, Nabwana M, Scholes D, et al. Depo-Provera worsens bone loss with TDF-containing ART initiation in young women. Program and abstracts of the 23rd International AIDS Conference Virtual; July 6-10, 2020. Abstract OAB0105.
Back Next
Provided by USF Health

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

Supported by an educational grant from
Janssen Therapeutics, Division of Janssen Products, LP

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?